SCHEMBL13282986

SCHEMBL13282986

CCSc1nc2cccc(F)c2c(=O)n1NC(=O)Cc1cccc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.47
RAB9A P51151 2/20 0.45
PDE7A Q13946 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
GLS O94925 2/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
MAPT P10636 2/20 0.39
TP53 P04637 1/20 0.39
LMNA P02545 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PRKACA P17612 1/20 0.38
ROCK1 Q13464 1/20 0.38
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378917 0.92 NPSR1 (0.56) NPSR1RAB9APDE7ACYP1A2CYP3A4
SCHEMBL13282996 0.91 HTT (0.44) NPSR1RAB9APDE7ACYP1A2CYP3A4
SCHEMBL13283034 0.90 NPSR1 (0.48) NPSR1RAB9APDE7ACYP1A2CYP3A4
SCHEMBL13283007 0.89 RAB9A (0.44) NPSR1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL13282985 0.87 NPSR1 (0.63) NPSR1RAB9APDE7ACYP1A2CYP3A4
SCHEMBL13102058 0.86 GLS (0.41) NPSR1GLSL3MBTL1MAPTLMNA
SCHEMBL13102401 0.82 GLS (0.39) GLSL3MBTL1MAPTMEN1KMT2A
SCHEMBL3378668 0.81 NPSR1 (0.45) NPSR1RAB9APDE7ACYP1A2CYP3A4
SCHEMBL13102065 0.80 PDE1C (0.42) GLSL3MBTL1MAPTSMN1; SMN2PRKACA
SCHEMBL2750839 0.78 ALDH1A1 (0.38) NPSR1RAB9AMAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS KCNQ1, KCNK17, KCNQ2 NPSR1 1722/4885RAB9A 560/4885PDE7A 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.